Japan Tobacco Inc.

Hironobu Nagamori

Hisashi Shinkai

Koichi Suzawa

Hiroshi Nakamura

Daisuke Takahashi

Takahisa Motomura

Kimiya Maeda

Toshio Taniguchi

Ikuo Mitani

Hirotsugu Ito

Satoru Kobayashi

Yuichi Nakagawa

Toru Morita

Yasunori Suzuki

Hiroshi Ueno

Dai Motoda

Akihiko Takahashi

Tomoya Miura

Masaki Yamashita

Kazuyuki Sugimoto

Kazuhito Ueyama

Yosuke Ogoshi

Takahiro Hotta

Masaki Takagi

Masatoshi Ueda

Tatsuya Nishimaru

Toshihiko Iwayama

Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Triazine compounds and pharmaceutical use thereof

The invention provides a compound having a GLUT9 inhibitory activity. The compound is of Formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Nitrogen-containing heteroaryl compound and pharmaceutical use thereof

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

Fluorene compound and pharmaceutical use thereof

The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

Pyrazole compound and pharmaceutical use thereof

A dibenzylamine compound represented by the formula (1) wherein Rand Rare each a Callyl group optionally substituted by halogen atoms and the like; R, Rand Rare each a hydrogen atom, a halogen atom and the like, or Rand Rmay form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is &#x2014;N(R)(R) and the like; ring B is an aryl group or a heterocyclic residue; Ris a hydrogen atom, a halogen atom, a nitro group, a Callyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

Dibenzylamine compounds and pharmaceutical use thereof

A dibenzylamine compound represented by the formula (1) wherein Rand Rare each a Calkyl group optionally substituted by halogen atoms and the like; R, Rand Rare each a hydrogen atom, a halogen atom and the like, or Rand Rmay form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is&#x2014;N(R) (R) and the like; ring B is an aryl group or a heterocyclic residue; Ris a hydrogen atom, a halogen atom, a nitro group, a Calkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

Dibenzylamine compound and medicinal use thereof

Growing community of inventors

Takatsuki, Japan

Hironobu Nagamori